triheptanoin (Dojolvi) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Triheptanoin, sold under the brand name Dojolvi, is a medication for the treatment of children and adults with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

glyceroltriheptanoate | glyceryl triheptanoate | triheptanoin | triheptanoin oil

Organizations (24)

Research & Development (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Fatty Acids (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Amyotrophic Lateral Sclerosis (Phase 1/Phase 2)

Ataxia Telangiectasia (Phase 2)

Cardiomyopathies (Phase 1/Phase 2)

Carnitine (Phase 2)

Carnitine O-Palmitoyltransferase (Phase 2)

Deficiency Diseases (Phase 2)

Epilepsy (Phase 2)

Fatty Acids (Phase 2)

Genetic Diseases, Inborn (Phase 2)

Glucose Metabolism Disorders (Phase 2)

Glucose Transporter Type 1 (Phase 3)

Glycogen Storage Disease Type I (Early Phase 1)

Glycogen Storage Disease Type III (Phase 2)

Glycogen Storage Disease Type IV (Phase 2)

Glycogen Storage Disease Type V (Phase 2)

Glycogen Storage Disease Type VII (Phase 2)

Heart Failure (Phase 1/Phase 2)

Huntington Disease (Phase 2)

Metabolism (Phase 1/Phase 2)

Migraine Disorders (Early Phase 1)

Pediatrics (Phase 2)

Rett Syndrome (Phase 2)

Sports Medicine (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 35
  • # of Trial Organizations: 24

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue